Non-small-cell lung carcinoma

Ribon Therapeutics Announces Publication in Cancer Cell of Pre-Clinical and Mechanism of Action Data for RBN-2397

Thursday, July 22, 2021 - 6:00pm

Ribon Therapeutics, a clinical stage biotechnology company developing therapeutics targeting stress support pathways, today announced the first publication in the peer-reviewed journal, Cancer Cell, of preclinical data from its lead asset, RBN-2397, a small molecule inhibitor of PARP7.

Key Points: 
  • Ribon Therapeutics, a clinical stage biotechnology company developing therapeutics targeting stress support pathways, today announced the first publication in the peer-reviewed journal, Cancer Cell, of preclinical data from its lead asset, RBN-2397, a small molecule inhibitor of PARP7.
  • PARP7 is overexpressed in a number of tumors, including squamous cell carcinoma of the lung (SCCL), which represents approximately 30% of all non-small cell lung cancers.
  • PARP7 is the first monoPARP to be targeted therapeutically and RBN-2397 is the first potent and selective PARP7 inhibitor to enter clinical development.
  • Ribon Therapeutics is a clinical stage biotechnology company developing therapeutics targeting novel enzyme families activated under cellular stress conditions that contribute to disease.

Agilent PD-L1 IHC 22C3 pharmDx Expands CE-IVD mark in Non-small Cell Lung Cancer (NSCLC)

Tuesday, July 20, 2021 - 5:34pm

Agilent Technologies Inc. (NYSE: A) today announced that the companys PD-L1 IHC 22C3 pharmDx assay is now labeled for expanded use in patients with non-small cell lung cancer (NSCLC) in the European Union.

Key Points: 
  • Agilent Technologies Inc. (NYSE: A) today announced that the companys PD-L1 IHC 22C3 pharmDx assay is now labeled for expanded use in patients with non-small cell lung cancer (NSCLC) in the European Union.
  • PD-L1 IHC 22C3 pharmDx can now be used as an aid in identifying NSCLC patients with tumor PD-L1 expression of Tumor Proportion Score (TPS) 50% for treatment with Libtayo (cemiplimab).
  • This further demonstrates Agilents commitment to partnering with leading pharmaceutical companies to develop IHC-based diagnostics for targeted cancer therapy.
  • 4th LuCE report on lung cancer: Early diagnosis and screening challenges in lung cancer.

eFFECTOR Therapeutics Announces Publication of Tomivosertib Preclinical Data in Cell Reports

Friday, July 16, 2021 - 1:00pm

This publication further validates the novel science on which eFFECTORs platform is built, said Steve Worland, Ph.D., president and CEO of eFFECTOR.

Key Points: 
  • This publication further validates the novel science on which eFFECTORs platform is built, said Steve Worland, Ph.D., president and CEO of eFFECTOR.
  • We are proud that our contributions have the potential to broaden the treatment landscape for those impacted by cancer.
  • Tomivosertib is being evaluated in KICKSTART, eFFECTORs randomized, double-blind, placebo-controlled Phase 2b study in non-small cell lung cancer (NSCLC) in combination with pembrolizumab.
  • Neither LWAC nor eFFECTOR gives any assurance that either LWAC or eFFECTOR or the combined company will achieve its expectations.

Preventing lung cancer's unwelcome return

Tuesday, July 13, 2021 - 1:00pm

Cold Spring Harbor Laboratory (CSHL) Visiting Scientist Raffaella Sordella investigated a similar problem that occurs in some lung cancers .

Key Points: 
  • Cold Spring Harbor Laboratory (CSHL) Visiting Scientist Raffaella Sordella investigated a similar problem that occurs in some lung cancers .
  • Approximately 15% of non-small cell lung cancers have a mutation in a growth receptor called EGFR, causing tumor cells to grow uncontrollably.
  • Researchers developed an effective drug that inhibits EGFR and kills cancer cells, but the tumor grows back later.
  • Understanding how resistance arises in lung cancer is key to figuring out how to eliminate a tumor.

Silverback Therapeutics Announces Clinical Supply Agreement with Regeneron to Evaluate SBT6050 in Combination with Libtayo® (cemiplimab), initially in HER2-expressing Non-Small Cell Lung and Gastric Cancers

Wednesday, July 7, 2021 - 12:30pm

We are eager to complete the ongoing dose escalation of SBT6050 combined with a PD-1 inhibitor, and look forward to working with Regeneron as we begin tumor-specific expansion cohorts.

Key Points: 
  • We are eager to complete the ongoing dose escalation of SBT6050 combined with a PD-1 inhibitor, and look forward to working with Regeneron as we begin tumor-specific expansion cohorts.
  • In the first quarter of 2021, Silverback initiated treatment in Part 3 of the Phase 1/1b study to evaluate the activity of SBT6050 in combination with a PD-1 inhibitor in dose escalation.
  • Under the terms of the agreement, Silverback will expand the ongoing Phase 1/1b trial to evaluate the combination of SBT6050 and Libtayo in tumor-specific dose expansion cohorts, initially in HER2-expressing non small cell lung cancer (NSCLC) and gastric cancer.
  • Libtayo is a PD-1 blocking antibody being jointly developed and commercialized by Regeneron and Sanofi.

FoundationOne®CDx Receives FDA-Approval as a Companion Diagnostic for ALUNBRIG® (brigatinib) to Identify Patients with ALK positive Metastatic Non-Small Cell Lung Cancer

Thursday, July 1, 2021 - 2:00pm

Non-small cell lung cancer (NSCLC) is the most common form of lung cancer, accounting for 85 percent of the estimated 1.8 million new cases of lung cancer diagnosed globally each year.

Key Points: 
  • Non-small cell lung cancer (NSCLC) is the most common form of lung cancer, accounting for 85 percent of the estimated 1.8 million new cases of lung cancer diagnosed globally each year.
  • Were proud to partner with Takeda to ensure patients with this serious condition have access to this important treatment option.
  • FoundationOne CDx, which now has 28 companion diagnostic claims, is the first and only FDA-approved tissue-based broad companion diagnostic that is clinically and analytically validated for solid tumors.
  • This latest approval reinforces FoundationOne CDxs ability to detect ALK rearrangements, which can be missed with alternate testing methods.

Achilles Therapeutics Enrolls First US Patient in Ongoing Phase I/IIa Study in Advanced Non-small Cell Lung Cancer

Thursday, July 1, 2021 - 1:00pm

CHIRON is an open-label, multi-center Phase I/IIa trial evaluating the safety, tolerability, and activity of clonal neoantigen T cell (cNeT) therapy as a single dose in adult patients with advanced metastatic non-small cell lung cancer (NSCLC).

Key Points: 
  • CHIRON is an open-label, multi-center Phase I/IIa trial evaluating the safety, tolerability, and activity of clonal neoantigen T cell (cNeT) therapy as a single dose in adult patients with advanced metastatic non-small cell lung cancer (NSCLC).
  • This first US patient was enrolled at the Moffitt Cancer Center in Tampa, FL where Dr. Benjamin Creelan is the Principal Investigator.
  • Achilles is a clinical-stage biopharmaceutical company developing precision T cell therapies targeting clonal neoantigens: protein markers unique to the individual that are expressed on the surface of every cancer cell.
  • The Company has two ongoing Phase I/IIa trials, the CHIRON trial in patients with advanced non-small cell lung cancer (NSCLC) and the THETIS trial in patients with recurrent or metastatic melanoma.

AmoyDx® Pan Lung Cancer PCR Panel Receives MHLW Approval as Companion Diagnostic for 9 Targeted Therapies for Use in Patients with Advanced Non-Small Cell Lung Cancer

Wednesday, June 30, 2021 - 5:01am

The AmoyDx PLC Panel has received approval for four driver genes (EGFR, ALK, ROS1, and BRAF) for nine associated targeted therapies in NSCLC.

Key Points: 
  • The AmoyDx PLC Panel has received approval for four driver genes (EGFR, ALK, ROS1, and BRAF) for nine associated targeted therapies in NSCLC.
  • With its high sensitivity and short turnaround time, The AmoyDx PLC Panel is expected to be an important clinical diagnostic in guiding treatment opportunities for NSCLC patients.
  • We are pleased to collaborate with AmoyDx and PREMIA in obtaining approval of the AmoyDx PLC Panel in Japan.
  • Detection of EGFR gene mutations, ALK fusion gene, ROS1 fusion gene, and BRAF gene mutations in nucleic acids extracted from cancer tissue

Iovance Biotherapeutics Announces Clinical Data for LN-145 in Non-Small Cell Lung Cancer

Tuesday, June 29, 2021 - 11:30am

The initial clinical results are available in a slide presentation on the Iovance website here .

Key Points: 
  • The initial clinical results are available in a slide presentation on the Iovance website here .
  • Iovance anticipates presenting additional Cohort 3B data at a medical meeting in the second half of 2021.
  • Friedrich Graf Finckenstein, M.D., Chief Medical Officer of Iovance, stated, There remains a very significant unmet need to increase response rates and prolong survival in the second line non-small cell lung cancer treatment setting.
  • In addition, the companys TIL cell therapy is being investigated in a registration-supporting study for the treatment of patients with locally advanced, recurrent or metastatic non-small cell lung cancer (NSCLC).

US Tissue Diagnostics Market Size, Share & Trends Analysis Report 2021-2028 by Technology & Product (IHC, Primary & Special Staining), Application (Breast Cancer, NSCLC) - ResearchAndMarkets.com

Monday, June 28, 2021 - 9:47am

The "US Tissue Diagnostics Market Size, Share & Trends Analysis Report by Technology & Product (IHC, Primary & Special Staining), Application (Breast Cancer, NSCLC), and Segment Forecasts, 2021-2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "US Tissue Diagnostics Market Size, Share & Trends Analysis Report by Technology & Product (IHC, Primary & Special Staining), Application (Breast Cancer, NSCLC), and Segment Forecasts, 2021-2028" report has been added to ResearchAndMarkets.com's offering.
  • The U.S. tissue diagnostics market size is estimated to reach USD 2.81 billion by 2028, registering a CAGR of 3.91% over the forecast period.
  • Tissue analysis provides significant information, which is difficult to understand using conventional molecular techniques.
  • Currently, companion diagnostic tests are rapidly being adopted by pharmaceutical companies for obtaining first-line therapy designations/approvals for their products.